Search Results - "Pal, Sumanta K"

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial by Motzer, Robert J., Robbins, Paul B., Powles, Thomas, Albiges, Laurence, Haanen, John B., Larkin, James, Mu, Xinmeng Jasmine, Ching, Keith A., Uemura, Motohide, Pal, Sumanta K., Alekseev, Boris, Gravis, Gwenaelle, Campbell, Matthew T., Penkov, Konstantin, Lee, Jae Lyun, Hariharan, Subramanian, Wang, Xiao, Zhang, Weidong, Wang, Jing, Chudnovsky, Aleksander, di Pietro, Alessandra, Donahue, Amber C., Choueiri, Toni K.

“…We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN Renal 101 trial ( n  = 886; NCT02684006 ), which demonstrated significantly…”
Get full text

TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients by Hossain, Dewan M S, Pal, Sumanta K, Moreira, Dayson, Duttagupta, Priyanka, Zhang, Qifang, Won, Haejung, Jones, Jeremy, D'Apuzzo, Massimo, Forman, Stephen, Kortylewski, Marcin

“…Recent advances in immunotherapy of advanced human cancers underscored the need to address and eliminate tumor immune evasion. The myeloid-derived suppressor…”
Get full text

S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites by Deng, Jiehui, Liu, Yong, Lee, Heehyoung, Herrmann, Andreas, Zhang, Wang, Zhang, Chunyan, Shen, Shudan, Priceman, Saul J., Kujawski, Maciej, Pal, Sumanta K., Raubitschek, Andrew, Hoon, Dave S.B., Forman, Stephen, Figlin, Robert A., Liu, Jie, Jove, Richard, Yu, Hua

“…Recent studies underscore the importance of myeloid cells in rendering distant organs hospitable for disseminating tumor cells to colonize. However, what…”
Get full text

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma by Pal, Sumanta K, Sonpavde, Guru, Agarwal, Neeraj, Vogelzang, Nicholas J, Srinivas, Sandy, Haas, Naomi B, Signoretti, Sabina, McGregor, Bradley A, Jones, Jeremy, Lanman, Richard B, Banks, Kimberly C, Choueiri, Toni K

“…Abstract Background Treatment of metastatic renal cell carcinoma (mRCC) typically entails mechanistically distinct agents across the first- and second-line…”
Get full text

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study by Ko, Jenny J, MD, Xie, Wanling, MS, Kroeger, Nils, MD, Lee, Jae-lyun, MD, Rini, Brian I, MD, Knox, Jennifer J, MD, Bjarnason, Georg A, MD, Srinivas, Sandy, MD, Pal, Sumanta K, MD, Yuasa, Takeshi, MD, Smoragiewicz, Martin, MD, Donskov, Frede, MD, Kanesvaran, Ravindran, MD, Wood, Lori, MD, Ernst, D Scott, MD, Agarwal, Neeraj, MD, Vaishampayan, Ulka N, MD, Rha, Sun-young, MD, Choueiri, Toni K, MD, Heng, Daniel Y C, Dr

“…Summary Background Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied in the…”
Get full text

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium by Dudani, Shaan, Graham, Jeffrey, Wells, J. Connor, Bakouny, Ziad, Pal, Sumanta K., Dizman, Nazli, Donskov, Frede, Porta, Camillo, de Velasco, Guillermo, Hansen, Aaron, Iafolla, Marco, Beuselinck, Benoit, Vaishampayan, Ulka N., Wood, Lori A., Liow, Elizabeth, Yan, Flora, Yuasa, Takeshi, Bjarnason, Georg A., Choueiri, Toni K., Heng, Daniel Y.C.

“…In metastatic renal-cell carcinoma (mRCC), recent data have shown efficacy of first-line ipilimumab and nivolumab (ipi-nivo) as well as immuno-oncology…”
Get full text

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) by Rini, Brian I., Battle, Dena, Figlin, Robert A., George, Daniel J., Hammers, Hans, Hutson, Tom, Jonasch, Eric, Joseph, Richard W., McDermott, David F., Motzer, Robert J., Pal, Sumanta K., Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.

“…The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with…”
Get full text

Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era by Pal, Sumanta K, Nelson, Rebecca A, Vogelzang, Nicholas

“…Recent phase III studies of targeted agents for metastatic renal cell carcinoma (mRCC) have generated median survival estimates that far exceed those observed…”
Get full text

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis by Sun, Maxine, Marconi, Lorenzo, Eisen, Tim, Escudier, Bernard, Giles, Rachel H., Haas, Naomi B., Harshman, Lauren C., Quinn, David I., Larkin, James, Pal, Sumanta K., Powles, Thomas, Ryan, Christopher W., Sternberg, Cora N., Uzzo, Robert, Choueiri, Toni K., Bex, Axel

“…Contradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for…”
Get full text

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer by Galsky, Matthew D., Pal, Sumanta K., Chowdhury, Simon, Harshman, Lauren C., Crabb, Simon J., Wong, Yu‐Ning, Yu, Evan Y., Powles, Thomas, Moshier, Erin L., Ladoire, Sylvain, Hussain, Syed A., Agarwal, Neeraj, Vaishampayan, Ulka N., Recine, Federica, Berthold, Dominik, Necchi, Andrea, Theodore, Christine, Milowsky, Matthew I., Bellmunt, Joaquim, Rosenberg, Jonathan E.

“…BACKGROUND Gemcitabine plus cisplatin (GC) has been adopted as a neoadjuvant regimen for muscle‐invasive bladder cancer despite the lack of Level I evidence in…”
Get full text

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma by Ernst, Matthew S., Navani, Vishal, Wells, J. Connor, Donskov, Frede, Basappa, Naveen, Labaki, Chris, Pal, Sumanta K., Meza, Luis, Wood, Lori A., Ernst, D. Scott, Szabados, Bernadett, McKay, Rana R., Parnis, Francis, Suarez, Cristina, Yuasa, Takeshi, Lalani, Aly-Khan, Alva, Ajjai, Bjarnason, Georg A., Choueiri, Toni K., Heng, Daniel Y.C.

“…This study demonstrates that the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model continues to risk stratify patients treated…”
Get full text

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4 by Hahn, Andrew W, Gill, David M, Pal, Sumanta K, Agarwal, Neeraj

“…The adaptive immune system plays an important role in eradicating malignant cells. Co-stimulatory and co-inhibitory signals to T cells though immune checkpoint…”
Get full text

Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis by Wu, Xiwei, Weng, Lihong, Li, Xuejun, Guo, Chao, Pal, Sumanta K, Jin, Jennifer M, Li, Yuping, Nelson, Rebecca A, Mu, Bing, Onami, Susan H, Wu, Jeffrey J, Ruel, Nora H, Wilczynski, Sharon P, Gao, Hanlin, Covarrubias, Maricela, Figlin, Robert A, Weiss, Lawrence M, Wu, Huiqing

“…Renal cell carcinoma (RCC) metastasis portends a poor prognosis and cannot be reliably predicted. Early determination of the metastatic potential of RCC may…”
Get full text

Metastasis in renal cell carcinoma: Biology and implications for therapy by Gong, Jun, Maia, Manuel Caitano, Dizman, Nazli, Govindarajan, Ameish, Pal, Sumanta K.

“…Although multiple advances have been made in systemic therapy for renal cell carcinoma (RCC), metastatic RCC remains incurable. In the current review, we focus…”
Get full text

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA by Agarwal, Neeraj, Pal, Sumanta K., Hahn, Andrew W., Nussenzveig, Roberto H., Pond, Gregory R., Gupta, Sumati V., Wang, Jue, Bilen, Mehmet A., Naik, Gurudatta, Ghatalia, Pooja, Hoimes, Christopher J., Gopalakrishnan, Dharmesh, Barata, Pedro C., Drakaki, Alexandra, Faltas, Bishoy M., Kiedrowski, Lesli A., Lanman, Richard B., Nagy, Rebecca J., Vogelzang, Nicholas J., Boucher, Kenneth M., Vaishampayan, Ulka N., Sonpavde, Guru, Grivas, Petros

“…BACKGROUND Biomarker‐guided clinical trials are increasingly common in metastatic urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue…”
Get full text

Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer by Yuh, Bertram E, Ruel, Nora, Wilson, Timothy G, Vogelzang, Nicholas, Pal, Sumanta K

“…Neoadjuvant chemotherapy for muscle invasive bladder cancer has been shown to confer a survival advantage in phase III studies. Although cisplatin and…”
Get more information

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond by Zhu, Jason, Armstrong, Andrew J, Friedlander, Terence W, Kim, Won, Pal, Sumanta K, George, Daniel J, Zhang, Tian

“…Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell…”
Get full text

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy by Pal, Sumanta K, Moreira, Dayson, Won, Haejung, White, Seok Woon, Duttagupta, Pryanka, Lucia, Marc, Jones, Jeremy, Hsu, JoAnn, Kortylewski, Marcin

“…Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate…”
Get full text

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations by Ross, Jeffrey S., Wang, Kai, Khaira, Depinder, Ali, Siraj M., Fisher, Huge A.G., Mian, Badar, Nazeer, Tipu, Elvin, Julia A., Palma, Norma, Yelensky, Roman, Lipson, Doron, Miller, Vincent A., Stephens, Philip J., Subbiah, Vivek, Pal, Sumanta K.

“…BACKGROUND In the current study, the authors present a comprehensive genomic profile (CGP)‐based study of advanced urothelial carcinoma (UC) designed to detect…”
Get full text

Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma by Necchi, Andrea, Madison, Russell, Pal, Sumanta K., Ross, Jeffrey S., Agarwal, Neeraj, Sonpavde, Guru, Joshi, Monika, Yin, Ming, Miller, Vincent A., Grivas, Petros, Chung, Jon H., Ali, Siraj M.

“…Characterization of the different genomic alterations (GAs) in urothelial carcinoma (UC), by site of origin, may identify contrasting therapeutic opportunities…”
Get full text